BR112019011681A2 - teste sorológico para controle terapêutico de carcinoma hpv16 positivo - Google Patents

teste sorológico para controle terapêutico de carcinoma hpv16 positivo Download PDF

Info

Publication number
BR112019011681A2
BR112019011681A2 BR112019011681-8A BR112019011681A BR112019011681A2 BR 112019011681 A2 BR112019011681 A2 BR 112019011681A2 BR 112019011681 A BR112019011681 A BR 112019011681A BR 112019011681 A2 BR112019011681 A2 BR 112019011681A2
Authority
BR
Brazil
Prior art keywords
antibodies
hpv16
capsid
patient
antigens
Prior art date
Application number
BR112019011681-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Hilfrich Ralf
Original Assignee
Abviris Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abviris Deutschland Gmbh filed Critical Abviris Deutschland Gmbh
Publication of BR112019011681A2 publication Critical patent/BR112019011681A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112019011681-8A 2016-12-13 2017-12-13 teste sorológico para controle terapêutico de carcinoma hpv16 positivo BR112019011681A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102016124171.7A DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen
DE102016124171.7 2016-12-13
PCT/EP2017/082506 WO2018108957A1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma

Publications (1)

Publication Number Publication Date
BR112019011681A2 true BR112019011681A2 (pt) 2019-10-15

Family

ID=61027644

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019011681-8A BR112019011681A2 (pt) 2016-12-13 2017-12-13 teste sorológico para controle terapêutico de carcinoma hpv16 positivo

Country Status (22)

Country Link
US (2) US10852303B2 (https=)
EP (1) EP3384292B1 (https=)
JP (2) JP7329244B2 (https=)
KR (1) KR102433541B1 (https=)
CN (1) CN110073219B (https=)
BR (1) BR112019011681A2 (https=)
CA (1) CA3045729A1 (https=)
CY (1) CY1124297T1 (https=)
DE (1) DE102016124171A1 (https=)
DK (1) DK3384292T3 (https=)
ES (1) ES2880489T3 (https=)
HR (1) HRP20211080T1 (https=)
HU (1) HUE054969T2 (https=)
LT (1) LT3384292T (https=)
PL (1) PL3384292T3 (https=)
PT (1) PT3384292T (https=)
RS (1) RS62135B1 (https=)
RU (1) RU2757629C2 (https=)
SI (1) SI3384292T1 (https=)
SM (1) SMT202100421T1 (https=)
WO (1) WO2018108957A1 (https=)
ZA (1) ZA201804516B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102022127779A1 (de) 2022-10-20 2024-04-25 Ralf Hilfrich Serologischer Test zum Nachweis von Antikörpern gegen HPV und Testkit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) * 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
US7067258B2 (en) * 2002-04-30 2006-06-27 Merck & Co., Inc. Human papillomavirus multiplexed assay
CN101245099A (zh) * 2007-02-14 2008-08-20 马润林 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
DE102010061028A1 (de) * 2010-12-03 2012-06-06 Ralf Hilfrich Schnelltest zum qualitativen und/oder quantitativen Bestimmen von Körperflüssigkeit enthaltenen Antikörpern gegen humane Papillomviren sowie Vorrichtung zum Durchführen des Schnelltests
DE102011053741A1 (de) * 2011-09-19 2013-03-21 Ralf Hilfrich Verfahren zum Überprüfen der Selbstheilung durch das Immunsystem eines mit humanen Papillomviren infizierten Menschen

Also Published As

Publication number Publication date
SI3384292T1 (sl) 2021-08-31
RU2757629C2 (ru) 2021-10-19
EP3384292B1 (en) 2021-04-21
KR102433541B1 (ko) 2022-08-18
LT3384292T (lt) 2021-07-26
KR20190097155A (ko) 2019-08-20
ZA201804516B (en) 2019-04-24
RS62135B1 (sr) 2021-08-31
CY1124297T1 (el) 2022-07-22
RU2019121882A3 (https=) 2021-04-09
RU2019121882A (ru) 2021-01-15
SMT202100421T1 (it) 2021-09-14
JP2020501162A (ja) 2020-01-16
JP7329244B2 (ja) 2023-08-18
US20190113516A1 (en) 2019-04-18
US11506667B2 (en) 2022-11-22
ES2880489T3 (es) 2021-11-24
CN110073219B (zh) 2023-09-05
CN110073219A (zh) 2019-07-30
US20200408768A1 (en) 2020-12-31
EP3384292A1 (en) 2018-10-10
JP2023029377A (ja) 2023-03-03
PL3384292T3 (pl) 2021-10-25
DK3384292T3 (da) 2021-06-28
WO2018108957A1 (en) 2018-06-21
HRP20211080T1 (hr) 2021-10-01
HUE054969T2 (hu) 2021-10-28
CA3045729A1 (en) 2018-06-21
US10852303B2 (en) 2020-12-01
DE102016124171A1 (de) 2018-06-14
PT3384292T (pt) 2021-07-22

Similar Documents

Publication Publication Date Title
De Jong et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine
JP4046949B2 (ja) 自己組立て組換えパピローマウイルスキャプシッド蛋白質
Jenison et al. Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope
JP2009521707A (ja) 疾患のバイオマーカーとしての脂肪生成アデノウイルス
Cason et al. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type‐16 (HPV‐16) in sera from patients with cervical intraepithelial neoplasia and children
Xiao et al. Observations on the expression of human papillomavirus major capsid protein in HeLa cells
Zhao et al. A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity
JP2019213536A (ja) Ｂ型肝炎ウイルス表面抗原のエピトープおよびこれに特異的に結合するｂ型肝炎ウイルス中和結合分子
US11506667B2 (en) Serologic test for therapy control of HPV16 positive carcinoma
CN108276491A (zh) 一种可特异性识别hpv18 l1蛋白的单克隆抗体及其应用
Gaarenstroom et al. Prognostic significance of serum antibodies to human papillomavirus‐16 E4 and E7 peptides in cervical cancer
Einstein Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines
Baay et al. Humoral immune response against proteins E6 and E7 in cervical carcinoma patients positive for human papilloma virus type 16 during treatment and follow-up
Crum et al. Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis
Egg et al. The Controversial Link Between Human Papillomavirus Infection and Esophageal Health: An Exploratory Translational Study
JP4945730B2 (ja) 粘膜指向性ヒトパピローマウイルス群の感染予防ワクチン抗原
Wu et al. Pseudotyped virus for papillomavirus
CN111205364A (zh) 抗hpv31l1的单克隆中和抗体及其应用
Huang et al. Systemic administration of a potent mouse monoclonal antibody provides multisite protection against HPV16 infection
Tosi et al. Use of antibodies against a synthetic peptide of the E6 protein of human papillomavirus (HPV) type 16 for the diagnosis of genital HPV lesions
Rajsri et al. Exploring the role of HPV: from Sexually transmitted infection to Oropharyngeal Cancers
Demeter et al. Human papillomaviruses
Hassen et al. Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women
Wang THE ROLE OF E6 PROTEIN IN HUMAN PAPILLOMAVIRUS ASSOCIATED UPPER AIRWAY DISEASES
EP1213299A1 (en) Immunogenic epitopes of human papilloma virus and uses thereof

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2859 DE 21-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.